WPA
RARE icon

West Paces Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

West Paces Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-255
Closed -$13.6K – 484
2017
Q3 		$13.6K Hold
255
– – 0.01% 304
2017
Q2 		$15.8K Hold
255
– – 0.01% 279
2017
Q1 		$17.3K Buy
255
+155
+155% +$11.8K 0.01% 268
2016
Q4 		$7.03K Buy
+100
New +$7.09K 0.01% 379

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

West Paces Advisors's RARE Position: Q4 2017 in Review

West Paces Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 255 shares — an estimated $13.6K sold.

West Paces Advisors first reported a position in RARE in Q4 2016 and held it in 4 quarters. The position peaked at $17.3K in Q1 2017. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • West Paces Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • West Paces Advisors sold 255 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $13.6K.
  • West Paces Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2016 and held it in 4 quarters.
  • West Paces Advisors's Ultragenyx Pharmaceutical position peaked at $17.3K in Q1 2017.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on West Paces Advisors's 13F filing for Q4 2017, filed 22 Dec 2023.